oAlert.pl

Medicines & supplements – Current GIS Alerts 2026

Found 791 alerts in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Recalled product: Fluconazole B. Braun 2 mg/ml

Fluconazole B. Braun 2 mg/ml

GIF Critical 04.08.2023

Cross‑contamination of infusion solutions was detected in the above-mentioned medicinal product batches, which may lead to administration of an incorrect substance or dose to the patient. Potential effects: poisoning, serious adverse reactions, allergic reactions, lack of efficacy, severe systemic complications.

Recalled product: Paracetamol B. Braun

Paracetamol B. Braun

GIF Critical 04.08.2023

detection of cross-contamination of infusion solutions in the above-mentioned series of medicinal products Potential effects: poisoning, unpredictable adverse reactions, lack of therapeutic efficacy, perioperative complications.

Recalled product: Lactulose-MIP

Lactulose-MIP

GIF Medium 01.08.2023

Deviations were identified in the product manufacturing process, so deterioration of its quality during the shelf life cannot be excluded, and therefore there is a potential risk to patient health. Potential effects: lack of treatment efficacy or unpredictable adverse reactions.

Recalled product: Lactulose-MIP

Lactulose-MIP

GIF Medium 01.08.2023

A deviation in the manufacturing process was identified; deterioration of product quality during the shelf life cannot be excluded, thus creating a risk to patient health. Potential effects: lack of therapeutic efficacy or adverse reactions.

Recalled product: Sabril

Sabril

GIF Critical 31.07.2023

Due to the detected presence of tiapride, a risk to the patient’s health or life cannot be excluded; the presence of trace amounts of tiapride may theoretically result in numerous serious and life‑threatening adverse reactions. Potential effects: severe, potentially life‑threatening adverse reactions.

Recalled product: Sabril

Sabril

GIF Critical 31.07.2023

The presence of tiapride above 0.3 ppm in vigabatrin products may theoretically lead to numerous serious and life‑threatening adverse reactions; a risk to the patient’s health or life cannot be excluded. Potential effects: serious adverse reactions, including life‑threatening events.

Recalled product: Pasta borowinowa lecznicza

Pasta borowinowa lecznicza

GIF Critical 28.07.2023

An excessive amount of Clostridium perfringens and the presence of Candida farmata/guilliermondii yeasts were detected, meaning the product does not meet microbiological purity requirements and may pose a health risk to patients when applied to the skin. Potential effects: skin infections, irritation, complications in immunocompromised individuals.

Recalled product: Tresuvi

Tresuvi

GIF Critical 24.07.2023

Unidentified solid particles were detected in the solution for infusion; due to the unknown nature of the contamination, a risk to patients’ health and life cannot be excluded. Potential effects: thrombotic complications, emboli, inflammatory reactions, life-threatening events.

Recalled product: Andepin

Andepin

GIF Medium 24.07.2023

Due to the detected increased content of a single impurity, a health risk for the patient taking this product cannot be excluded. Potential effects: poisoning, increased adverse reactions, complications of therapy.

Recalled product: Autostrzykawka Morfina Przeciwko Bólowi

Autostrzykawka Morfina Przeciwko Bólowi

GIF Critical 18.07.2023

Due to the detected solution discoloration that does not comply with quality requirements, the risk to the patient’s health and life cannot be excluded. Potential effects: poisoning, severe adverse reactions, life-threatening complications.

Recalled product: Sirdalud MR

Sirdalud MR

GIF High 07.07.2023

It is not possible to guarantee specification-compliant active substance release after 2 hours until the end of the shelf-life, which may affect the quality and safety of product use. Potential effects: lack of treatment efficacy or increased adverse effects.

Recalled product: Sirdalud MR

Sirdalud MR

GIF Medium 07.07.2023

It is not possible to guarantee specification-compliant release of tizanidine hydrochloride after 2 hours, and the cause is not fully understood, so the impact on product quality and safety of use cannot be predicted. Potential effects: lack of treatment efficacy or adverse effects related to incorrect dosing.

Recalled product: Detimedac 200 mg

Detimedac 200 mg

GIF Critical 03.07.2023

The pink discoloration may be caused by degradation of the active substance, which may pose an increased risk to the patient. Potential effects: lack of treatment efficacy, complications of oncological therapy, possible adverse effects related to degradation products.

Recalled product: Detimedac 500 mg

Detimedac 500 mg

GIF Critical 03.07.2023

The pink discoloration may be caused by degradation of the active substance, which may pose an increased risk to the patient. Potential effects: lack of treatment efficacy, possible adverse reactions.

Recalled product: Detimedac 100 mg

Detimedac 100 mg

GIF Critical 03.07.2023

Pink discoloration may be caused by degradation of the active substance, which may represent an increased risk to the patient. Potential effects: reduced treatment efficacy or unpredictable adverse reactions.

Recalled product: Lorabex

Lorabex

GIF Critical 29.06.2023

It was suspected that the product might not meet quality requirements (out-of-specification results for lorazepam content and related substances), but testing of samples taken from the market confirmed correct quality of the batch. Potential effects: possible alteration of drug action, lack of efficacy or adverse effects.

Recalled product: Mebelin

Mebelin

GIF Medium 26.06.2023

Due to the reduced values of active substance release in the product, the risk to patient health resulting from decreased drug efficacy cannot be excluded. Potential effects: lack of treatment efficacy, possible worsening of disease symptoms.

Recalled product: PALIFREN LONG

PALIFREN LONG

GIF Medium 16.06.2023

A reduced content of the active substance paliperidone palmitate and an increased particle size compared to requirements were found, which may lead to reduced medicinal efficacy and a risk to patient health. Potential effects: reduced treatment efficacy, worsening of disease symptoms.

Recalled product: Duracef

Duracef

GIF Medium 14.06.2023

Testing showed a lower value of cefadroxil release within 30 minutes, so a risk to patient health due to lack of drug efficacy cannot be excluded. Potential effects: lack of treatment effectiveness, possible disease complications.

Recalled product: APAP dla dzieci FORTE

APAP dla dzieci FORTE

GIF Medium 26.05.2023

The suspension in the bottle contained gas bubbles, was foamed, had increased volume, and in several cases was non-uniform and separated into layers, which may indicate a significant quality defect of the medicine. Potential effects: incorrect dosing, reduced effectiveness, possible adverse reactions.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.